Tag: licensing
-
Novartis Licenses Biomaterial for Cancer Immunotherapy
Drug maker Novartis is licensing from a lab at Harvard University a biocompatible material designed to provide delivery of treatments that invoke the immune system to fight cancer.
-
Smartphone App, Device Shown to Measure Blood Pressure
A smartphone-based system and app were shown in a pilot study with human subjects to measure a person’s blood pressure with about the same accuracy as some cuff devices normally used to gauge blood pressure.
-
Evotec Acquiring Sanofi Infectious Disease Portfolio
Drug discovery company Evotec AG is licensing 10 infectious disease R&D programs and their 100 employees from drug maker Sanofi, and opening new labs for this work in Lyon, France.
-
Company Formed to Develop Cancer Cell Therapies
The MD Anderson Cancer Center in Houston is starting Optera Therapeutics Corp., a new company to commercialize its research on treating cancer with a patients’ own immune system cells.
-
Trial Shows Reduction in Huntington Disease Protein
First results from a clinical trial show an experimental therapy reduces production of a protein damaging nerve cells in people with Huntington disease.
-
Start-Up Developing Blood-Brain Barrier Treatments
A medical school professor in Singapore is starting a biotechnology company to discover and develop new drugs for neurological disorders based on his research with mechanisms for crossing the blood-brain barrier.
-
Techniques Devised to Boost Gene Therapy Success
An engineering team at Washington University in St. Louis is developing mechanical and electronic processes to improve the success of inserting large, complex therapeutic molecules like DNA into cells.
-
Pharma, Biotech Partner on Neuro Therapies in $1.1B Deal
Voyager Therapeutics, a developer of gene therapies for neurological disorders, is collaborating with drug maker AbbVie on treatments for diseases resulting from the build-up of damaging proteins in the brain, as in Alzheimer’s disease.
-
Engineered Virus Shows Promise in Some Brain Tumors
A clinical trial testing a common virus modified to generate a specific immune response dramatically reduced deadly brain tumors in a small group of patients and extended their survival for years, but most other patients had only limited success.
-
Biotechs Collaborate on Immunotherapies in $1.2B Deal
Two biotechnology companies developing cancer therapies harnessing the immune system are partnering on new treatments for solid tumor and blood-related cancers.